Turn Therapeutics Inc. TTRX 深 沪
已收盘 07-02 16:00:00 美东时间
7.12
+0.270
+3.94%
华盛通- 最 高7.32
- 今 开6.94
- 成交量 2.06万股
- 最 低 6.83
- 昨 收 6.85
- 总市值 21.21万
- 52周最高 26.50
- 市盈率 静 --
- 换手率 0.07%
- 52周最低 2.5701
- 委 比 41.86%
- 总股本 2.98万
- 历史最高 26.50
- 量 比 0.34
- 振 幅 7.15%
- 历史最低 2.5701
- 每 手 1
- 风险率 1.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Turn Therapeutics Announces Interim Analysis Findings From First 50 Completed Subjects Enrolled In Ongoing Randomized, Double-Blind, Vehicle-Controlled Phase 2 Clinical Trial Evaluating GX-03 In Adults With Atopic Dermatitis
92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70.4% achieved a 75% reduction in 4 weeks (EASI-75); 44.4% achieved a 90% reduction in 4 weeks (EASI-90); and 51.9%
06-01 20:36
Turn Therapeutics CEO to Present at Jefferies Conference
The latest update is out from Turn Therapeutics Inc ( ($TTRX) ). On May 19, 202...
05-19 20:46
Turn Therapeutics Appoints Former FDA Chief to Lead GX-03
Turn Therapeutics Inc ( ($TTRX) ) has shared an update. Turn Therapeutics Inc.,...
05-18 21:16
Turn Therapeutics Q1 EPS $(0.03) Misses $(0.02) Estimate
Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 200 percent decrease over losses of $(0.01) per share from
05-12 04:22
Turn Therapeutics Q4 EPS $0.01
Turn Therapeutics (NASDAQ:TTRX) reported quarterly earnings of $0.01 per share.
04-01 04:39
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor
Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor Turn Therapeutics Inc. has appointed Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs. Dr. Redfield will provide strategic guidance on the clinical development and public health aspects of the company's lea
02-17 21:02
Turn Therapeutics Unveils Novel Topical Immunomodulation Approach Targeting Eczema and Inflammatory Diseases
Turn Therapeutics Unveils Novel Topical Immunomodulation Approach Targeting Eczema and Inflammatory Diseases Turn Therapeutics Inc. has released a corporate presentation outlining its development of first-in-class, precision, non-systemic immunomodulation therapies targeting IL-36 and key downstream
02-09 21:05
Turn Therapeutics to Present Dermatology Pipeline Update at Major Healthcare Conferences
Turn Therapeutics to Present Dermatology Pipeline Update at Major Healthcare Conferences Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company specializing in targeted inflammatory and immunology therapies for dermatology, will participate in two upcoming healthcare conferenc
02-09 21:01
美股大行评级 | 存储再获大行看好！花旗、瑞银和美银齐上调西部数据、希捷科技等公司目标价；PNC金融服务获6家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Soleno Therapeutics"买入"评级，目标价从110美元升至120美元；富国银行：维持Soleno Therapeutics"超配"评级，目标价从106美元升至114美元
01-21 11:42
D. Boral Capital Maintains Buy on Turn Therapeutics, Maintains $8 Price Target
D. Boral Capital analyst Jason Kolbert maintains Turn Therapeutics (NASDAQ:TTRX) with a Buy and maintains $8 price target.
01-20 20:16
